v3.26.1
Equity-Based Compensation
6 Months Ended
Jun. 30, 2026
Equity-Based Compensation  
Equity-Based Compensation
12.
Equity-Based Compensation

Restricted Common Stock

The following table provides a summary of the unvested restricted common stock award activity during the six months ended June 30, 2026:

 

NUMBER OF SHARES

 

 

WEIGHTED-
AVERAGE
GRANT DATE FAIR
VALUE PER
SHARE

 

Unvested restricted common stock as of December 31, 2025

 

 

637,594

 

 

$

5.69

 

Vested

 

 

(362,995

)

 

 

5.04

 

Forfeited

 

 

(2,204

)

 

 

7.62

 

Unvested restricted common stock as of June 30, 2026

 

 

272,395

 

 

$

6.54

 

The fair value of restricted common stock awards vested during the three and six months ended June 30, 2026 was $0.9 million and $1.8 million, respectively.

Stock Options and Restricted Stock Units

In July 2023, in connection with the IPO, the Company’s Board of Directors (the “Board”) and stockholders approved the 2023 Equity Incentive Plan (the “2023 Plan”), which became effective on July 13, 2023. The 2023 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, awards of restricted stock, restricted stock units and other stock-based awards. As of June 30, 2026, 7,788,719 shares of common stock were available for future grant under the 2023 Plan. The number of shares available for grant and issuance under the 2023 Plan is automatically increased on January 1 of each year by a number of shares equal to up to 5% of the outstanding shares of common stock on such date.

The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted with the following assumptions:

 

THREE MONTHS ENDED JUNE 30,

 

SIX MONTHS ENDED JUNE 30,

 

2026

 

2026

Risk-free interest rate

 

4.1% - 4.3%

 

3.6% - 4.3%

Expected dividend yield

 

0.0%

 

0.0%

Expected term (in years)

 

5.5 - 6.25

 

5.5 - 6.25

Expected volatility

 

73.1% - 75.0%

 

73.1% - 75.2%

The following table provides a summary of stock option activity during the six months ended June 30, 2026:

 

OPTIONS

 

 

WEIGHTED-
AVERAGE
EXERCISE
PRICE

 

 

WEIGHTED-
AVERAGE
REMAINING
CONTRACTUAL TERM
(IN YEARS)

 

 

AGGREGATE
INTRINSIC
VALUE
(IN THOUSANDS)

 

Outstanding as of December 31, 2025

 

 

5,610,444

 

 

$

36.95

 

 

 

8.56

 

 

$

216,170

 

Granted

 

 

1,558,954

 

 

 

76.62

 

 

 

 

 

 

 

Exercised

 

 

(380,664

)

 

 

33.77

 

 

 

 

 

 

 

Forfeited

 

 

(163,263

)

 

 

44.35

 

 

 

 

 

 

 

Outstanding as of June 30, 2026

 

 

6,625,471

 

 

$

46.29

 

 

 

8.42

 

 

$

572,738

 

Exercisable as of June 30, 2026

 

 

2,486,113

 

 

$

36.03

 

 

 

7.99

 

 

$

240,395

 

The total intrinsic value of options exercised during the three and six months ended June 30, 2026 was $16.5 million and $22.9 million, respectively.

The following table provides a summary of the unvested restricted stock unit activity under the 2023 Plan during the six months ended June 30, 2026:

 

NUMBER OF
SHARES

 

 

WEIGHTED-
AVERAGE
GRANT DATE FAIR
VALUE PER SHARE

 

Unvested restricted stock units as of December 31, 2025

 

 

177,615

 

 

$

39.36

 

Granted

 

 

213,851

 

 

 

76.98

 

Vested

 

 

(56,322

)

 

 

52.16

 

Forfeited

 

 

(13,645

)

 

 

59.25

 

Unvested restricted stock units as of June 30, 2026

 

 

321,499

 

 

$

61.30

 

The fair value of restricted stock units vested during the three and six months ended June 30, 2026 was $1.5 million and $2.9 million, respectively.

2023 Employee Stock Purchase Plan

In July 2023, the Board adopted and the Company’s stockholders approved the 2023 Employee Stock Purchase Plan (the “ESPP”), which became effective on July 13, 2023. The ESPP provides that eligible employees may contribute up to 15% of their eligible earnings toward the semi-annual purchase of the Company’s common stock, subject to any plan limitations. The purchase period under the ESPP has a duration of six months, and the purchase price with respect to each purchase period is equal to 85% of the lesser of (i) the fair market value of the Company’s common stock at the commencement of the applicable six-month purchase period or (ii) the fair market value of the Company’s common stock on the exercise date. As of June 30, 2026, 88,354 shares have been issued under the ESPP and 2,138,677 shares remain available for issuance.

The following table presents the classification of equity-based compensation expense related to equity awards granted to employees, executives, and service providers (in thousands):

 

THREE MONTHS ENDED
JUNE 30,

 

 

SIX MONTHS ENDED
JUNE 30,

 

 

2026

 

 

2025

 

 

2026

 

2025

 

Research and development expense

 

$

9,129

 

 

$

5,538

 

 

$

17,656

 

$

10,910

 

General and administrative expense

 

 

7,534

 

 

 

5,806

 

 

 

16,162

 

 

11,560

 

Total

 

$

16,663

 

 

$

11,344

 

 

$

33,818

 

$

22,470

 

As of June 30, 2026, the total unrecognized compensation expense related to the Company’s stock options, unvested restricted stock and ESPP was $168.3 million, which the Company expects to recognize over a weighted-average period of approximately 2.5 years.